TY  - GEN
N2  - Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide, with high morbidity, high mortality, and few therapeutic options outside of surgery, standard cytotoxic chemotherapy, and radiation. Epidermal growth factor receptor (EGFR) is overexpressed in up to 90% of HNSCC and is associated with poor outcome. An EGFR monoclonal antibody, cetuximab, is the only FDA-approved cancer intrinsic molecular targeted therapy for HNSCC; however, resistance eventually occurs in all patients. In my graduate studies, functional screens, including a small-molecule kinase inhibitor screen and siRNA screening panels, were used to identify agents that synergized with EGFR inhibitors in reducing viability in HNSCC patient-derived tumor cells. Bioinformatics analysis was performed to determine the coverage by the drugs on the inhibitor assay of genomic alterations in the HNSCC The Cancer Genome Atlas (TCGA) cohort.
DO  - 10.6083/m48915d7
DO  - DOI
AB  - Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide, with high morbidity, high mortality, and few therapeutic options outside of surgery, standard cytotoxic chemotherapy, and radiation. Epidermal growth factor receptor (EGFR) is overexpressed in up to 90% of HNSCC and is associated with poor outcome. An EGFR monoclonal antibody, cetuximab, is the only FDA-approved cancer intrinsic molecular targeted therapy for HNSCC; however, resistance eventually occurs in all patients. In my graduate studies, functional screens, including a small-molecule kinase inhibitor screen and siRNA screening panels, were used to identify agents that synergized with EGFR inhibitors in reducing viability in HNSCC patient-derived tumor cells. Bioinformatics analysis was performed to determine the coverage by the drugs on the inhibitor assay of genomic alterations in the HNSCC The Cancer Genome Atlas (TCGA) cohort.
T1  - Functional analyses of patient-derived tumor cells reveal potential targeted therapies for HNSCC
DA  - 2017
AU  - Ouyang, Xiaoming
L1  - https://digitalcollections.ohsu.edu/record/7661/files/Ouyang.Xiaoming.2017.pdf
PB  - Oregon Health and Science University
PY  - 2017
ID  - 7661
L4  - https://digitalcollections.ohsu.edu/record/7661/files/Ouyang.Xiaoming.2017.pdf
KW  - Receptor Protein-Tyrosine Kinases
KW  - Humans
KW  - Squamous Cell Carcinoma of Head and Neck
KW  - Head and Neck Neoplasms
KW  - Molecular Targeted Therapy
TI  - Functional analyses of patient-derived tumor cells reveal potential targeted therapies for HNSCC
Y1  - 2017
L2  - https://digitalcollections.ohsu.edu/record/7661/files/Ouyang.Xiaoming.2017.pdf
LK  - https://digitalcollections.ohsu.edu/record/7661/files/Ouyang.Xiaoming.2017.pdf
UR  - https://digitalcollections.ohsu.edu/record/7661/files/Ouyang.Xiaoming.2017.pdf
ER  -